Jazz Pharmaceuticals resumed with a Buy at Goldman Sachs
Upside potential from analyst upgrade.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Upside potential from analyst upgrade.
What happened, with direct paths to the underlying reporting
Goldman Sachs targets $337 with Jazz; current price about $234.88.
Target: $337
Posted price: $234.88
Analyst firm: Goldman Sachs
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.